TY - JOUR T1 - Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis JF - European Respiratory Journal JO - Eur Respir J SP - 1503 LP - 1507 DO - 10.1183/13993003.01249-2016 VL - 48 IS - 5 AU - Giovanni Sotgiu AU - Simon Tiberi AU - Lia D'Ambrosio AU - Rosella Centis AU - Jan Willem Alffenaar AU - Jose A. Caminero AU - Marcos Abdo Arbex AU - Valentina Alarcon Guizado AU - Alena Aleksa AU - Simone Dore AU - Mina Gaga AU - Gina Gualano AU - Heinke Kunst AU - Marie-Christine Payen AU - Aurora Jazmín Roby Arias AU - Alena Skrahina AU - Ivan Solovic AU - Giorgia Sulis AU - Marina Tadolini AU - Alimuddin Zumla AU - Giovanni Battista Migliori Y1 - 2016/11/01 UR - http://erj.ersjournals.com/content/48/5/1503.abstract N2 - Multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are growing clinical and public health concerns, with an estimated worldwide incidence and mortality of 480 000 and 190 000 cases, respectively (2014) [1]. The World Health Organization (WHO) End TB Strategy reiterates the MDR-/XDR-TB threat and the solutions to control the epidemic [2]. Unfortunately, large proportions of patients with resistant TB do not have access to adequate diagnostics and treatment yet, while treatment success rates remain suboptimal (as demonstrated in the largest retrospective cohort of MDR-TB patients, i.e., TB caused by Mycobacterium tuberculosis isolates resistant to at least isoniazid and rifampicin) and decrease further with resistance patterns beyond XDR-TB [3].Evaluation of drug resistances is needed to identify candidates for the shorter regimen in MDR-TB hot spots http://ow.ly/wZV33022VXtThe authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions and policies of their institutions.All authors contributed to the conception of the study, data analysis, interpretation of the results, drafting of the manuscript and approval of the final version.Members of the International Carbapenem Study Group: M. Abdo Arbex (Brazil), O.W. Akkerman (The Netherlands), E. Alarcon Arrascue (Peru), V. Alarcon Guizado (Peru), A. Aleksa (Belarus), J.W. Alffenaar (The Netherlands), J. Artsukevich (Belarus), V. Avchynka (Belarus), J.A. Caminero (Spain), R. Centis (Italy), L. D'Ambrosio (Italy), S. De Lorenzo (Italy), S. Dore (Italy), M. Gaga (Greece), G. Gualano (Italy), A.J. Roby Arias (Ecuador), E.H. Bonini (Brazil), F.A. Chong Marín (Ecuador), G. de Vries (The Netherlands), S. Dore (Italy), H. Kunst (UK), A. Matteelli (Italy), G.B. Migliori (Italy), C. Moschos (Greece), F. Palmieri (Italy), A. Papavasileiou (Greece), M.C. Payen (Belgium), A. Piana (Italy), A. Scardigli (France), A. Skrahina (Belarus), I. Solovic (Slovakia), G. Sotgiu (Italy), A. Spanevello (Italy), G. Sulis (Italy), M. Tadolini (Italy), S. Tiberi (UK), D. Vargas Vasquez (Peru), P. Viggiani (Italy), V. White (UK), A. Zumla (UK). ER -